Microbiome Therapeutics Market Analysis Report, Growth Drivers and Future Outlook
[Research Report] The microbiome therapeutics market size is expected to grow from US$ 375.92 million in 2022 and to reach a value of US$ 813.38 million by 2030; it is anticipated to record a CAGR of 10.1% from 2022 to 2030.
Market Insights and Analyst View:
Microbiome therapeutics, also referred to as microbiome-based therapies or interventions, are medical procedures that use human microbiome's potential to treat a variety of illnesses. In the healthcare and life science industries, microbiome therapeutics are a new and quickly expanding market. This market is being driven by advancements in microbiome research, which are raising awareness of the gut-brain connection and offering the possibility of developing cutting-edge treatments for a range of medical conditions. The pipeline of microbiome therapeutics is dynamic and diverse, aimed at tackling an extensive array of medical conditions and offering novel treatments that harness the human microbiome. More microbiome-based treatments may become available as this field of study develops, opening up new avenues for market expansion. There is a growing need for novel and more efficient treatments due to the rising prevalence of illnesses such as metabolic disorders, obesity, irritable bowel syndrome, and inflammatory bowel disease. Microbiome-based treatments present a cutting-edge method of treating these ailments. This consequently generates a large window of opportunity for microbiome therapeutics market expansion in the near future.
Growth Drivers and Challenges:
Microbiome therapeutics are aimed at modifying the gut microbiome by using bacteriophages, bacteriocins, antibiotics, native or synthetic bacteria, or subtractive or modulatory treatment. By offering individualized, harmonized, dependable, and long-lasting therapy, this strategy can overcome the limitations of traditional therapies. The global therapeutics market has demonstrated its enormous economic potential. Studies have shown promising results in using microbiome therapeutics for conditions such as inflammatory bowel disease, obesity, and even mental health disorders. Ongoing research is also exploring the potential of microbiome-based interventions in areas of cancer treatment, diabetes management, and cardiovascular health. Further, the incidence of gastrointestinal illnesses increases with age, and the GI Alliance data from February 2021 estimates that almost 20 million Americans have chronic digestive diseases, and over 62 million Americans receive a diagnosis of gastrointestinal diseases each year. The International Foundation for Gastrointestinal Disorders, Inc. (IFFGD) released statistics showing that GERD prevalence ranges from 18% to 28% in North America, 23% in South America, and 9–26% in Europe. Therefore, in the upcoming years, the increasing frequency of gastrointestinal disorders will fuel the market expansion.
By understanding the intricate relationship between microbiome and disease development, scientists are developing personalized treatments that target the root cause of the problem rather than merely managing symptoms. As knowledge expands and technologies advance, microbiome therapeutics have the potential to become a cornerstone of modern medicine, offering hope for improved health outcomes for individuals affected by a range of diseases.
Technological advancements have facilitated the development of targeted interventions. By understanding the specific microbial species that are associated with certain diseases or conditions, researchers can develop therapies that specifically target those microbes. This personalized approach has the potential to be more effective and have fewer side effects compared to traditional broad-spectrum antibiotics. In addition to advancements in sequencing technology, other technological innovations have contributed to the development of microbiome therapeutics. Furthermore, there has been progress in the development of synthetic biology tools that allow for the engineering of microbial communities with desired functions. This opens up new possibilities for designing microbiome-based therapies that can be tailored to individual patients.
The process of identifying and isolating specific beneficial microorganisms, as well as producing them in large quantities, can be expensive and time-consuming. Additionally, ensuring the safety and efficacy of these therapeutics requires rigorous testing and regulatory approval, further adding to the cost. The personalized nature of microbiome therapeutics adds another layer of complexity and cost. Each individual's microbiome is unique, meaning that treatments may need to be tailored to their specific microbial composition. This requires extensive analysis and testing that are cost-intensive and time-consuming, thereby hindering the market growth for microbiome therapeutics.
Customize Research To Suit Your Requirement
We can optimize and tailor the analysis and scope which is unmet through our standard offerings. This flexibility will help you gain the exact information needed for your business planning and decision making.
Microbiome Therapeutics Market: Strategic Insights
Market Size Value in US$ 375.92 million in 2022 Market Size Value by US$ 813.38 million by 2030 Growth rate CAGR of 10.1% from 2022 to 2030 Forecast Period 2022 - 2030 Base Year 2022
Mrinal
Have a question?
Mrinal will walk you through a 15-minute call to present the report’s content and answer all queries if you have any.
Speak to Analyst
Customize Research To Suit Your Requirement
We can optimize and tailor the analysis and scope which is unmet through our standard offerings. This flexibility will help you gain the exact information needed for your business planning and decision making.
Microbiome Therapeutics Market: Strategic Insights
| Market Size Value in | US$ 375.92 million in 2022 |
| Market Size Value by | US$ 813.38 million by 2030 |
| Growth rate | CAGR of 10.1% from 2022 to 2030 |
| Forecast Period | 2022 - 2030 |
| Base Year | 2022 |
Mrinal
Have a question?
Mrinal will walk you through a 15-minute call to present the report’s content and answer all queries if you have any.
Speak to Analyst
Report Segmentation and Scope:
The microbiome therapeutics market is divided on the basis of type, application, and end user. Based on type, the microbiome therapeutics market is segmented into therapeutics and procedures. By application, the microbiome therapeutics market is segmented into metabolic disorders and obesity, C. difficile infection, and inflammatory bowel diseases. In terms of end users, the microbiome therapeutics market is classified as hospitals and clinics, ambulatory surgery centers, and home care. Based on geography, the microbiome therapeutics market is divided into North America (the US, Canada, and Mexico), Europe (the UK, Germany, France, Italy, Spain, and the Rest of Europe), Asia Pacific (China, Japan, India, South Korea, Australia, and the Rest of Asia Pacific), Middle East & Africa (the UAE, Saudi Arabia, South Africa, and the Rest of Middle East & Africa), and South & Central America (Brazil, Argentina, and the Rest of South & Central America).
Segmental Analysis:
Based on type, the microbiome therapeutics market is segmented into therapeutics and procedures. Fecal microbiome therapeutic technique is an emerging technique that has proven to be highly effective in patients with recurring Clostridioides difficile infection (CDI). Growing FMT product approvals by the Food and Drug Administration (FDA) for preventing the recurrence of CDI is fueling the growth of the segment. For instance, in November 2022, the US FDA approved Rebyota, the first fecal microbiota product used for the prevention of CDI recurrence in individuals aged above 18 years.
Based on application, the microbiome therapeutics market is classified into metabolic disorders and obesity, C. difficile infection, inflammatory bowel diseases and others. In 2022, the C. difficile infection segment held the largest share of the market and is expected to register the highest CAGR during 2022–2030. When someone takes antibiotics, good bacteria in the gut are destroyed for a few months. During this time, patients can get sick from Clostridioides difficile, a bacteria that often causes severe or even deadly diarrhea. According to CDC, in 2021, ~118,000 hospitalized patients suffered from C. difficile infection in the US. To prevent and treat C. difficile infection, the gut microbiome of the patient needs to be increased by giving microbiome therapeutics. Due to the increase in the number of C. difficile infections, companies are focusing on developing microbiome therapeutics for the treatment. For instance, in April 2023, the US FDA approved Vowst, the first fecal microbiota used to prevent the recurrence of C. difficile infection.
Based on end user, the microbiome therapeutics market is classified into hospitals and clinics, ambulatory surgery centers, home care, and others. In 2022, the hospitals and clinics segment held the largest share of the market, and it is expected to register the highest CAGR during 2022–2030. Hospitals are the fastest-growing end users of the microbiome therapeutics market. Hospitals are the primary healthcare centers patients seek for their first aid and treatment. The number of patients visiting hospitals is comparatively higher than other healthcare centers. These centers offer various services and provide good-quality treatment to patients. In many hospitals, the treatment fee is reimbursed; also, medicines are readily available in these healthcare centers. The implementation of advanced treatment technologies in hospitals has paved the way for improved and early detection of disease, as well as supported research related to disease treatment. Medical services are increasingly offered due to their rising affordability of treatment and awareness among people. It is a part of the ecosystem of many countries, as it contributes significantly toward the country’s GDP growth.
Microbiome Therapeutics Market Report Scope
Regional Analysis:
Based on geography, the microbiome therapeutics market is divided into North America, Europe, Asia Pacific, Middle East & Africa, and South & Central America. North America is the most significant contributor to the growth of the microbiome therapeutics market. The increasing understanding of the importance of the human microbiome in maintaining health and preventing diseases has led researchers in the US to explore microbiome-based interventions as a promising approach to treating various conditions. Additionally, the dominance of this country in the microbiome therapeutics market is mainly attributed to its well-developed research infrastructure that favors the development of innovative treatments. Technological advancements in gene sequencing and bioinformatics enable the study and alteration of the microbiome, facilitating the development of personalized microbiome-based interventions. The trend toward personalized medicine aligns well with tailormade microbiome therapeutics. Collaborations between academia, industry, and government organizations are also fueling research and development efforts, accelerating the translation of scientific discoveries into commercial products. Regulatory support and investment in the field further contribute to market growth, as regulatory bodies recognize the potential of microbiome therapeutics and provide guidance for their development and approval. An emphasis on research and innovation has yielded a significant understanding of the impact of gut microbiota on health, providing a robust foundation for microbiome-based therapeutics. A supportive regulatory environment for biotechnology and pharmaceuticals in Canada has encouraged companies to invest in microbiome-focused research and development. Additionally, increased venture capital investments and government funding have infused capital into this research. In January 2020, the Government of Canada, along with its partners, invested US$ 18 million in crucial microbiome research.
Asia Pacific is expected to be the fastest-growing market in the coming years. The microbiome therapeutics market in Japan is experiencing significant growth due to the increasing awareness and research on the human microbiome's impact on health. This has prompted pharmaceutical and biotech companies to invest in microbiome-based therapies. The aging population in Japan and the associated rise in age-related disorders, including gastrointestinal issues and metabolic conditions, create a strong demand for novel treatment options. Microbiome therapeutics, with their potential to provide personalized and effective solutions, are well-suited to address these healthcare challenges. Moreover, a favorable regulatory environment and government initiatives to support microbiome R&D play a crucial role in the microbiome therapeutics market growth in Japan.
Competitive Landscape and Key Companies:
Enterome, Finch Therapeutics Group Inc, Caelus Health, Ferring Pharmaceuticals, Pendulum Therapeutics Inc., AOBiome, Seres Therapeutics, Vedanta Biosciences, COST-BRY Pty Ltd (BiomeBank), and YSOPIA Bioscienceare are a few prominent players operating in the microbiome therapeutics market. These companies focus on expanding service offerings to meet the growing consumer demand worldwide. Their global presence allows them to serve a large set of customers, subsequently allowing them to expand their market share.
Report Coverage
Revenue forecast, Company Analysis, Industry landscape, Growth factors, and Trends
Segment Covered
Type, Application, End User and Geography
Regional Scope
North America, Europe, Asia Pacific, Middle East & Africa, South & Central America
Country Scope
This text is related
to country scope.
Frequently Asked Questions
The gut microbiota in maintaining human health and inflow of funds to ameliorate microbiome discovery pipeline bolster the microbiome therapeutics market size. However, the high cost of development and production hinders the microbiome therapeutics market growth.
Microbiome therapeutics, also referred to as microbiome-based therapies or interventions, are medical procedures that try to use the human microbiome's potential to treat and promote a variety of illnesses. In the healthcare and life science industries, microbiome therapeutics are a new and quickly expanding market. This market is being driven by advancements in microbiome research, which are raising awareness of the gut-brain connection and offering the possibility of developing cutting-edge treatments for a range of medical conditions.
Fecal microbiome therapeutic technique is an emerging technique that has proven to be highly effective in patients with recurring Clostridioides difficile infection (CDI). Growing FMT product approvals by the Food and Drug Administration (FDA) for preventing the recurrence of CDI is fueling the growth of the segment. For instance, in November 2022, the US FDA approved Rebyota, the first fecal microbiota product used for the prevention of CDI recurrence in individuals aged above 18 years.
The microbiome therapeutics market is expected to be valued at US$ 813.38 million in 2030.
The microbiome therapeutics market was valued at US$ 375.92 million in 2022.
The microbiome therapeutics market has major market players, including Enterome, Finch Therapeutics Group Inc, Caelus Health, Ferring Pharmaceuticals, Pendulum Therapeutics Inc., AOBiome, Seres Therapeutics, Vedanta Biosciences, COST-BRY Pty Ltd (BiomeBank) and YSOPIA Bioscience.
In 2022, the hospitals and clinics segment held the largest share of the market, and it is expected to register the highest CAGR during 2022–2030. Hospitals are the fastest-growing end users of the microbiome therapeutics market. Hospitals are the primary healthcare centers patients seek for their first aid and treatment. The number of patients visiting hospitals is comparatively higher than other healthcare centers. These centers offer various services and provide good-quality treatment to patients. In many hospitals, the treatment fee is reimbursed; also, medicines are readily available in these healthcare centers. The implementation of advanced treatment technologies in hospitals has paved the way for improved and early detection of disease, as well as supported research related to disease treatment..
In 2022, the C. difficile infection segment held the largest share of the market and is expected to register the highest CAGR during 2022–2030. When someone takes antibiotics, good bacteria in the gut are destroyed for a few months. During this time, patients can get sick from Clostridioides difficile, a bacteria that often causes severe or even deadly diarrhea. According to CDC, in 2021, ~118,000 hospitalized patients suffered from C. difficile infection in the US. To prevent and treat C. difficile infection, the gut microbiome of the patient needs to be increased by giving microbiome therapeutics. Due to the increase in the number of C. difficile infections, companies are focusing on developing microbiome therapeutics for the treatment. For instance, in April 2023, the US FDA approved Vowst, the first fecal microbiota used to prevent the recurrence of C. difficile infection.
1. Introduction
1.1 The Insight Partners Research Report Guidance
1.2 Market Segmentation
2. Executive Summary
2.1 Microbiome Therapeutics Market, by Geography
3. Research Methodology
3.1 Coverage
3.2 Secondary Research
3.3 Primary Research
4. Microbiome Therapeutics Market Landscape
4.1 Overview
4.2 PEST Analysis
4.2.1 Global PEST Analysis
5. Microbiome Therapeutics Market - Key Industry Dynamics
5.1 Market Drivers:
5.1.1 Potential of Gut Microbiota in Maintaining Human Health
5.1.2 Inflow of Funds to Ameliorate Microbiome Discovery Pipeline
5.2 Market Restraints
5.2.1 High Cost of Development and Production
5.3 Market Opportunities
5.3.1 Increasing R&D to Gain Better Understanding of Human Microbiome
5.4 Future Trends
5.4.1 Technological Advancement in Human Microbiome Therapeutics
5.5 Impact Analysis:
6. Microbiome Therapeutics Market - Global Market Analysis
6.1 Microbiome Therapeutics Market Revenue (US$ Mn), 2020 – 2030
7. Global Microbiome Therapeutics Market – Revenue and Forecast to 2030 – by Type
7.1 Overview
7.2 Microbiome Therapeutics Market Revenue Share, by Type, 2022 & 2030 (%)
7.3 Procedure
7.3.1 Overview
7.3.2 Procedure: Microbiome Therapeutics Market – Revenue and Forecast to 2030 (US$ Million)
7.4 Therapeutics
7.4.1 Overview
7.4.2 Therapeutics: Microbiome Therapeutics Market – Revenue and Forecast to 2030 (US$ Million)
7.4.2.1 Global: Microbiome Therapeutics Market, by Therapeutics, 2020–2030 (US$ Million)
8. Global Microbiome Therapeutics Market – Revenue and Forecast to 2030 – by Application
8.1 Overview
8.2 Microbiome Therapeutics Market Revenue Share, by Application, 2022 & 2030 (%)
8.3 Metabolic Disorder and Obesity
8.3.1 Overview
8.3.2 Metabolic Disorder and Obesity: Microbiome Therapeutics Market – Revenue and Forecast to 2030 (US$ Million)
8.4 C. Difficile Infection (CDI)
8.4.1 Overview
8.4.2 C. Difficile Infection (CDI): Microbiome Therapeutics Market – Revenue and Forecast to 2030 (US$ Million)
8.5 Inflammatory Bowel Disease
8.5.1 Overview
8.5.2 Inflammatory Bowel Disease: Microbiome Therapeutics Market – Revenue and Forecast to 2030 (US$ Million)
8.6 Others
8.6.1 Overview
8.6.2 Others: Microbiome Therapeutics Market – Revenue and Forecast to 2030 (US$ Million)
9. Global Microbiome Therapeutics Market – Revenue and Forecast to 2030 – by End User
9.1 Overview
9.2 Microbiome Therapeutics Market Revenue Share, by End User, 2022 & 2030 (%)
9.3 Hospitals and Clinics
9.3.1 Overview
9.3.2 Hospitals and Clinics: Microbiome Therapeutics Market – Revenue and Forecast to 2030 (US$ Million)
9.4 Ambulatory Surgical Centers
9.4.1 Overview
9.4.2 Ambulatory Surgical Centers: Microbiome Therapeutics Market – Revenue and Forecast to 2030 (US$ Million)
9.5 Homecare
9.5.1 Overview
9.5.2 Homecare: Microbiome Therapeutics Market – Revenue and Forecast to 2030 (US$ Million)
9.6 Others
9.6.1 Overview
9.6.2 Others: Microbiome Therapeutics Market – Revenue and Forecast to 2030 (US$ Million)
10. Microbiome Therapeutics Market - Geographical Analysis
10.1 North America Microbiome Therapeutics Market, Revenue and Forecast To 2030
10.1.1 Overview
10.1.2 North America Microbiome Therapeutics Market Revenue and Forecast to 2030 (US$ Mn)
10.1.3 North America: Microbiome Therapeutics Market, by Type, 2020–2030 (US$ Million)
10.1.3.1 North America: Microbiome Therapeutics Market, by Therapeutics, 2020–2030 (US$ Million)
10.1.4 North America: Microbiome Therapeutics Market, by Application, 2020–2030 (US$ Million)
10.1.5 North America: Microbiome Therapeutics Market, by End User, 2020–2030 (US$ Million)
10.1.6 North America Microbiome Therapeutics Market, by Country
10.1.6.1 US
10.1.6.1.1 Overview
10.1.6.1.2 US Microbiome Therapeutics Market Revenue and Forecast to 2030 (US$ Mn)
10.1.6.1.3 US: Microbiome Therapeutics Market, by Type, 2020–2030 (US$ Million)
10.1.6.1.3.1 US: Microbiome Therapeutics Market, by Therapeutics, 2020–2030 (US$ Million)
10.1.6.1.4 US: Microbiome Therapeutics Market, by Application, 2020–2030 (US$ Million)
10.1.6.1.5 US: Microbiome Therapeutics Market, by End User, 2020–2030 (US$ Million)
10.1.6.2 Canada
10.1.6.2.1 Overview
10.1.6.2.2 Canada Microbiome Therapeutics Market Revenue and Forecast to 2030 (US$ Mn)
10.1.6.2.3 Canada: Microbiome Therapeutics Market, by Type, 2020–2030 (US$ Million)
10.1.6.2.3.1 Canada: Microbiome Therapeutics Market, by Therapeutics, 2020–2030 (US$ Million)
10.1.6.2.4 Canada: Microbiome Therapeutics Market, by Application, 2020–2030 (US$ Million)
10.1.6.2.5 Canada: Microbiome Therapeutics Market, by End User, 2020–2030 (US$ Million)
10.1.6.3 Mexico
10.1.6.3.1 Overview
10.1.6.3.2 Mexico Microbiome Therapeutics Market Revenue and Forecast to 2030 (US$ Mn)
10.1.6.3.3 Mexico: Microbiome Therapeutics Market, by Type, 2020–2030 (US$ Million)
10.1.6.3.3.1 Mexico: Microbiome Therapeutics Market, by Therapeutics, 2020–2030 (US$ Million)
10.1.6.3.4 Mexico: Microbiome Therapeutics Market, by Application, 2020–2030 (US$ Million)
10.1.6.3.5 Mexico: Microbiome Therapeutics Market, by End User, 2020–2030 (US$ Million)
10.2 Europe Microbiome Therapeutics Market, Revenue and Forecast to 2030
10.2.1 Overview
10.2.2 Europe Microbiome Therapeutics Market Revenue and Forecast to 2030 (US$ Mn)
10.2.3 Europe: Microbiome Therapeutics Market, by Type, 2020–2030 (US$ Million)
10.2.3.1 Europe: Microbiome Therapeutics Market, by Therapeutics, 2020–2030 (US$ Million)
10.2.4 Europe: Microbiome Therapeutics Market, by Application, 2020–2030 (US$ Million)
10.2.5 Europe: Microbiome Therapeutics Market, by End User, 2020–2030 (US$ Million)
10.2.6 Europe Microbiome Therapeutics Market, by Country
10.2.6.1 UK
10.2.6.1.1 Overview
10.2.6.1.2 UK Microbiome Therapeutics Market Revenue and Forecast to 2030 (US$ Mn)
10.2.6.1.3 UK: Microbiome Therapeutics Market, by Type, 2020–2030 (US$ Million)
10.2.6.1.3.1 UK: Microbiome Therapeutics Market, by Therapeutics, 2020–2030 (US$ Million)
10.2.6.1.4 UK: Microbiome Therapeutics Market, by Application, 2020–2030 (US$ Million)
10.2.6.1.5 UK: Microbiome Therapeutics Market, by End User, 2020–2030 (US$ Million)
10.2.6.2 Germany
10.2.6.2.1 Overview
10.2.6.2.2 Germany Microbiome Therapeutics Market Revenue and Forecast to 2030 (US$ Mn)
10.2.6.2.3 Germany: Microbiome Therapeutics Market, by Type, 2020–2030 (US$ Million)
10.2.6.2.3.1 Germany: Microbiome Therapeutics Market, by Therapeutics, 2020–2030 (US$ Million)
10.2.6.2.4 Germany: Microbiome Therapeutics Market, by Application, 2020–2030 (US$ Million)
10.2.6.2.5 Germany: Microbiome Therapeutics Market, by End User, 2020–2030 (US$ Million)
10.2.6.3 France
10.2.6.3.1 Overview
10.2.6.3.2 France Microbiome Therapeutics Market Revenue and Forecast to 2030 (US$ Mn)
10.2.6.3.3 France: Microbiome Therapeutics Market, by Type, 2020–2030 (US$ Million)
10.2.6.3.3.1 France: Microbiome Therapeutics Market, by Therapeutics, 2020–2030 (US$ Million)
10.2.6.3.4 France: Microbiome Therapeutics Market, by Application, 2020–2030 (US$ Million)
10.2.6.3.5 France: Microbiome Therapeutics Market, by End User, 2020–2030 (US$ Million)
10.2.6.4 Italy
10.2.6.4.1 Overview
10.2.6.4.2 Italy Microbiome Therapeutics Market Revenue and Forecast to 2030 (US$ Mn)
10.2.6.4.3 Italy: Microbiome Therapeutics Market, by Type, 2020–2030 (US$ Million)
10.2.6.4.3.1 Italy: Microbiome Therapeutics Market, by Therapeutics, 2020–2030 (US$ Million)
10.2.6.4.4 Italy: Microbiome Therapeutics Market, by Application, 2020–2030 (US$ Million)
10.2.6.4.5 Italy: Microbiome Therapeutics Market, by End User, 2020–2030 (US$ Million)
10.2.6.5 Spain
10.2.6.5.1 Overview
10.2.6.5.2 Spain Microbiome Therapeutics Market Revenue and Forecast to 2030 (US$ Mn)
10.2.6.5.3 Spain: Microbiome Therapeutics Market, by Type, 2020–2030 (US$ Million)
10.2.6.5.3.1 Spain: Microbiome Therapeutics Market, by Therapeutics, 2020–2030 (US$ Million)
10.2.6.5.4 Spain: Microbiome Therapeutics Market, by Application, 2020–2030 (US$ Million)
10.2.6.5.5 Spain: Microbiome Therapeutics Market, by End User, 2020–2030 (US$ Million)
10.2.6.7 Rest of Europe
10.2.6.7.1 Overview
10.2.6.7.2 Rest of Europe Microbiome Therapeutics Market Revenue and Forecast to 2030 (US$ Mn)
10.2.6.7.3 Rest of Europe: Microbiome Therapeutics Market, by Type, 2020–2030 (US$ Million)
10.2.6.7.3.1 Rest of Europe: Microbiome Therapeutics Market, by Therapeutics, 2020–2030 (US$ Million)
10.2.6.7.4 Rest of Europe: Microbiome Therapeutics Market, by Application, 2020–2030 (US$ Million)
10.2.6.7.5 Rest of Europe: Microbiome Therapeutics Market, by End User, 2020–2030 (US$ Million)
10.3 Asia Pacific Microbiome Therapeutics Market, Revenue and Forecast to 2030
10.3.1 Overview
10.3.2 Asia Pacific Microbiome Therapeutics Market Revenue and Forecast to 2030 (US$ Mn)
10.3.3 Asia Pacific: Microbiome Therapeutics Market, by Type, 2020–2030 (US$ Million)
10.3.3.1 Asia Pacific: Microbiome Therapeutics Market, by Therapeutics, 2020–2030 (US$ Million)
10.3.4 Asia Pacific: Microbiome Therapeutics Market, by Application, 2020–2030 (US$ Million)
10.3.5 Asia Pacific: Microbiome Therapeutics Market, by End User, 2020–2030 (US$ Million)
10.3.6 Asia Pacific Microbiome Therapeutics Market, by Country
10.3.6.1 China
10.3.6.1.1 Overview
10.3.6.1.2 China Microbiome Therapeutics Market Revenue and Forecast to 2030 (US$ Mn)
10.3.6.1.3 China: Microbiome Therapeutics Market, by Type, 2020–2030 (US$ Million)
10.3.6.1.3.1 China: Microbiome Therapeutics Market, by Therapeutics, 2020–2030 (US$ Million)
10.3.6.1.4 China: Microbiome Therapeutics Market, by Application, 2020–2030 (US$ Million)
10.3.6.1.5 China: Microbiome Therapeutics Market, by End User, 2020–2030 (US$ Million)
10.3.6.2 Japan
10.3.6.2.1 Overview
10.3.6.2.2 Japan Microbiome Therapeutics Market Revenue and Forecast to 2030 (US$ Mn)
10.3.6.2.3 Japan: Microbiome Therapeutics Market, by Type, 2020–2030 (US$ Million)
10.3.6.2.3.1 Japan: Microbiome Therapeutics Market, by Therapeutics, 2020–2030 (US$ Million)
10.3.6.2.4 Japan: Microbiome Therapeutics Market, by Application, 2020–2030 (US$ Million)
10.3.6.2.5 Japan: Microbiome Therapeutics Market, by End User, 2020–2030 (US$ Million)
10.3.6.3 India
10.3.6.3.1 Overview
10.3.6.3.2 India Microbiome Therapeutics Market Revenue and Forecast to 2030 (US$ Mn)
10.3.6.3.3 India: Microbiome Therapeutics Market, by Type, 2020–2030 (US$ Million)
10.3.6.3.3.1 India: Microbiome Therapeutics Market, by Therapeutics, 2020–2030 (US$ Million)
10.3.6.3.4 India: Microbiome Therapeutics Market, by Application, 2020–2030 (US$ Million)
10.3.6.3.5 India: Microbiome Therapeutics Market, by End User, 2020–2030 (US$ Million)
10.3.6.4 Australia
10.3.6.4.1 Overview
10.3.6.4.2 Australia Microbiome Therapeutics Market Revenue and Forecast to 2030 (US$ Mn)
10.3.6.4.3 Australia: Microbiome Therapeutics Market, by Type, 2020–2030 (US$ Million)
10.3.6.4.3.1 Australia: Microbiome Therapeutics Market, by Therapeutics, 2020–2030 (US$ Million)
10.3.6.4.4 Australia: Microbiome Therapeutics Market, by Application, 2020–2030 (US$ Million)
10.3.6.4.5 Australia: Microbiome Therapeutics Market, by End User, 2020–2030 (US$ Million)
10.3.6.5 South Korea
10.3.6.5.1 Overview
10.3.6.5.2 South Korea Microbiome Therapeutics Market Revenue and Forecast to 2030 (US$ Mn)
10.3.6.5.3 South Korea: Microbiome Therapeutics Market, by Type, 2020–2030 (US$ Million)
10.3.6.5.3.1 South Korea: Microbiome Therapeutics Market, by Therapeutics, 2020–2030 (US$ Million)
10.3.6.5.4 South Korea: Microbiome Therapeutics Market, by Application, 2020–2030 (US$ Million)
10.3.6.5.5 South Korea: Microbiome Therapeutics Market, by End User, 2020–2030 (US$ Million)
10.3.6.7 Rest of Asia Pacific
10.3.6.7.1 Overview
10.3.6.7.2 Rest of Asia Pacific Microbiome Therapeutics Market Revenue and Forecast to 2030 (US$ Mn)
10.3.6.7.3 Rest of Asia Pacific: Microbiome Therapeutics Market, by Type, 2020–2030 (US$ Million)
10.3.6.7.3.1 Rest of Asia Pacific: Microbiome Therapeutics Market, by Therapeutics, 2020–2030 (US$ Million)
10.3.6.7.4 Rest of Asia Pacific: Microbiome Therapeutics Market, by Application, 2020–2030 (US$ Million)
10.3.6.7.5 Rest of Asia Pacific: Microbiome Therapeutics Market, by End User, 2020–2030 (US$ Million)
10.4 Middle East & Africa Microbiome Therapeutics Market, Revenue and Forecast to 2030
10.4.1 Overview
10.4.2 Middle East & Africa Microbiome Therapeutics Market Revenue and Forecast to 2030 (US$ Mn)
10.4.3 Middle East & Africa: Microbiome Therapeutics Market, by Type, 2020–2030 (US$ Million)
10.4.3.1 Middle East & Africa: Microbiome Therapeutics Market, by Therapeutics, 2020–2030 (US$ Million)
10.4.4 Middle East & Africa: Microbiome Therapeutics Market, by Application, 2020–2030 (US$ Million)
10.4.5 Middle East & Africa: Microbiome Therapeutics Market, by End User, 2020–2030 (US$ Million)
10.4.5.1 Middle East & Africa Microbiome Therapeutics Market, by Country
10.4.5.2 Saudi Arabia
10.4.5.2.1 Overview
10.4.5.2.2 Saudi Arabia Microbiome Therapeutics Market Revenue and Forecast to 2030 (US$ Mn)
10.4.5.2.3 Saudi Arabia: Microbiome Therapeutics Market, by Type, 2020–2030 (US$ Million)
10.4.5.2.3.1 Saudi Arabia: Microbiome Therapeutics Market, by Therapeutics, 2020–2030 (US$ Million)
10.4.5.2.4 Saudi Arabia: Microbiome Therapeutics Market, by Application, 2020–2030 (US$ Million)
10.4.5.2.5 Saudi Arabia: Microbiome Therapeutics Market, by End User, 2020–2030 (US$ Million)
10.4.5.3 South Africa
10.4.5.3.1 Overview
10.4.5.3.2 South Africa Microbiome Therapeutics Market Revenue and Forecast to 2030 (US$ Mn)
10.4.5.3.3 South Africa: Microbiome Therapeutics Market, by Type, 2020–2030 (US$ Million)
10.4.5.3.3.1 South Africa: Microbiome Therapeutics Market, by Therapeutics, 2020–2030 (US$ Million)
10.4.5.3.4 South Africa: Microbiome Therapeutics Market, by Application, 2020–2030 (US$ Million)
10.4.5.3.5 South Africa: Microbiome Therapeutics Market, by End User, 2020–2030 (US$ Million)
10.4.5.4 UAE
10.4.5.4.1 Overview
10.4.5.4.2 UAE Microbiome Therapeutics Market Revenue and Forecast to 2030 (US$ Mn)
10.4.5.4.3 UAE: Microbiome Therapeutics Market, by Type, 2020–2030 (US$ Million)
10.4.5.4.3.1 UAE: Microbiome Therapeutics Market, by Therapeutics, 2020–2030 (US$ Million)
10.4.5.4.4 UAE: Microbiome Therapeutics Market, by Application, 2020–2030 (US$ Million)
10.4.5.4.5 UAE: Microbiome Therapeutics Market, by End User, 2020–2030 (US$ Million)
10.4.5.5 Rest of Middle East Africa
10.4.5.5.1 Overview
10.4.5.5.2 Rest of Middle East Africa Microbiome Therapeutics Market Revenue and Forecast to 2030 (US$ Mn)
10.4.5.5.3 Rest of Middle East Africa: Microbiome Therapeutics Market, by Type, 2020–2030 (US$ Million)
10.4.5.5.3.1 Rest of Middle East Africa: Microbiome Therapeutics Market, by Therapeutics, 2020–2030 (US$ Million)
10.4.5.5.4 Rest of Middle East Africa: Microbiome Therapeutics Market, by Application, 2020–2030 (US$ Million)
10.4.5.5.5 Rest of Middle East Africa: Microbiome Therapeutics Market, by End User, 2020–2030 (US$ Million)
10.5 South & Central America Microbiome Therapeutics Market, Revenue and Forecast to 2030
10.5.1 Overview
10.5.2 South & Central America Microbiome Therapeutics Market Revenue and Forecast to 2030 (US$ Mn)
10.5.3 South & Central America: Microbiome Therapeutics Market, by Type, 2020–2030 (US$ Million)
10.5.3.1 South & Central America: Microbiome Therapeutics Market, by Therapeutics, 2020–2030 (US$ Million)
10.5.4 South & Central America: Microbiome Therapeutics Market, by Application, 2020–2030 (US$ Million)
10.5.5 South & Central America: Microbiome Therapeutics Market, by End User, 2020–2030 (US$ Million)
10.5.6 South & Central America Microbiome Therapeutics Market, by Country
10.5.6.1 Brazil
10.5.6.1.1 Overview
10.5.6.1.2 Brazil Microbiome Therapeutics Market Revenue and Forecast to 2030 (US$ Mn)
10.5.6.1.3 Brazil: Microbiome Therapeutics Market, by Type, 2020–2030 (US$ Million)
10.5.6.1.3.1 Brazil: Microbiome Therapeutics Market, by Therapeutics, 2020–2030 (US$ Million)
10.5.6.1.4 Brazil: Microbiome Therapeutics Market, by Application, 2020–2030 (US$ Million)
10.5.6.1.5 Brazil: Microbiome Therapeutics Market, by End User, 2020–2030 (US$ Million)
10.5.6.2 Argentina
10.5.6.2.1 Overview
10.5.6.2.2 Argentina Microbiome Therapeutics Market Revenue and Forecast to 2030 (US$ Mn)
10.5.6.2.3 Argentina: Microbiome Therapeutics Market, by Type, 2020–2030 (US$ Million)
10.5.6.2.3.1 Argentina: Microbiome Therapeutics Market, by Therapeutics, 2020–2030 (US$ Million)
10.5.6.2.4 Argentina: Microbiome Therapeutics Market, by Application, 2020–2030 (US$ Million)
10.5.6.2.5 Argentina: Microbiome Therapeutics Market, by End User, 2020–2030 (US$ Million)
10.5.6.3 Rest of South & Central America
10.5.6.3.1 Overview
10.5.6.3.2 Rest of South & Central America Microbiome Therapeutics Market Revenue and Forecast to 2030 (US$ Mn)
10.5.6.3.3 Rest of South & Central America: Microbiome Therapeutics Market, by Type, 2020–2030 (US$ Million)
10.5.6.3.3.1 Rest of South & Central America: Microbiome Therapeutics Market, by Therapeutics, 2020–2030 (US$ Million)
10.5.6.3.4 Rest of South & Central America: Microbiome Therapeutics Market, by Application, 2020–2030 (US$ Million)
10.5.6.3.5 Rest of South & Central America: Microbiome Therapeutics Market, by End User, 2020–2030 (US$ Million)
11. Microbiome Therapeutics Market – Industry Landscape
11.1 Overview
11.2 Growth Strategies in Microbiome Therapeutics Market
11.3 Inorganic Growth Strategies
11.3.1 Overview
11.4 Organic Growth Strategies
11.4.1 Overview
12. Company Profiles
12.1 Enterome
12.1.1 Key Facts
12.1.2 Business Description
12.1.3 Products and Services
12.1.4 Financial Overview
12.1.5 SWOT Analysis
12.1.6 Key Developments
12.2 Finch Therapeutics Group Inc
12.2.1 Key Facts
12.2.2 Business Description
12.2.3 Products and Services
12.2.4 Financial Overview
12.2.5 SWOT Analysis
12.2.6 Key Developments
12.3 Caelus Health
12.3.1 Key Facts
12.3.2 Business Description
12.3.3 Products and Services
12.3.4 Financial Overview
12.3.5 SWOT Analysis
12.3.6 Key Developments
12.4 Ferring Pharmaceuticals
12.4.1 Key Facts
12.4.2 Business Description
12.4.3 Products and Services
12.4.4 Financial Overview
12.4.5 SWOT Analysis
12.4.6 Key Developments
12.5 Pendulum Therapeutics INC
12.5.1 Key Facts
12.5.2 Business Description
12.5.3 Products and Services
12.5.4 Financial Overview
12.5.5 SWOT Analysis
12.5.6 Key Developments
12.6 AOBiome
12.6.1 Key Facts
12.6.2 Business Description
12.6.3 Products and Services
12.6.4 Financial Overview
12.6.5 SWOT Analysis
12.6.6 Key Developments
12.7 Seres Therapeutics
12.7.1 Key Facts
12.7.2 Business Description
12.7.3 Products and Services
12.7.4 Financial Overview
12.7.5 SWOT Analysis
12.7.6 Key Developments
12.8 Vedanta Biosciences
12.8.1 Key Facts
12.8.2 Business Description
12.8.3 Products and Services
12.8.4 Financial Overview
12.8.5 SWOT Analysis
12.8.6 Key Developments
12.9 COST-BRY Pty Ltd (BiomeBank)
12.9.1 Key Facts
12.9.2 Business Description
12.9.3 Products and Services
12.9.4 Financial Overview
12.9.5 SWOT Analysis
12.9.6 Key Developments
12.10 YSOPIA Bioscience
12.10.1 Key Facts
12.10.2 Business Description
12.10.3 Products and Services
12.10.4 Financial Overview
12.10.5 SWOT Analysis
12.10.6 Key Developments
13. Appendix
13.1 About Us
13.2 Glossary of Terms
List of Tables
Table 1. Microbiome Therapeutics Market Segmentation
Table 2. Global Microbiome Therapeutics Market, by Therapeutics– Revenue and Forecast to 2030 (US$ Million)
Table 3. North America Microbiome Therapeutics Market, by Type– Revenue and Forecast to 2030 (US$ Million)
Table 4. North America Microbiome Therapeutics Market, by Therapeutics– Revenue and Forecast to 2030 (US$ Million)
Table 5. North America Microbiome Therapeutics Market, by Application – Revenue and Forecast to 2030 (US$ Million)
Table 6. North America Microbiome Therapeutics Market, by End User – Revenue and Forecast to 2030 (US$ Million)
Table 7. US Microbiome Therapeutics Market, by Type – Revenue and Forecast to 2030 (US$ Million)
Table 8. US Microbiome Therapeutics Market, by Therapeutics– Revenue and Forecast to 2030 (US$ Million)
Table 9. US Microbiome Therapeutics Market, by Application– Revenue and Forecast to 2030 (US$ Million)
Table 10. US Microbiome Therapeutics Market, by End User– Revenue and Forecast to 2030 (US$ Million)
Table 11. Canada Microbiome Therapeutics Market, by Type – Revenue and Forecast to 2030 (US$ Million)
Table 12. Canada Microbiome Therapeutics Market, by Therapeutics– Revenue and Forecast to 2030 (US$ Million)
Table 13. Canada Microbiome Therapeutics Market, by Application– Revenue and Forecast to 2030 (US$ Million)
Table 14. Canada Microbiome Therapeutics Market, by End User– Revenue and Forecast to 2030 (US$ Million)
Table 15. Mexico Microbiome Therapeutics Market, by Type – Revenue and Forecast to 2030 (US$ Million)
Table 16. Mexico Microbiome Therapeutics Market, by Therapeutics– Revenue and Forecast to 2030 (US$ Million)
Table 17. Mexico Microbiome Therapeutics Market, by Application– Revenue and Forecast to 2030 (US$ Million)
Table 18. Mexico Microbiome Therapeutics Market, by End User– Revenue and Forecast to 2030 (US$ Million)
Table 19. Europe Microbiome Therapeutics Market, by Type – Revenue and Forecast to 2030 (US$ Million)
Table 20. Europe Microbiome Therapeutics Market, by Therapeutics– Revenue and Forecast to 2030 (US$ Million)
Table 21. Europe Microbiome Therapeutics Market, by Application – Revenue and Forecast to 2030 (US$ Million)
Table 22. Europe Microbiome Therapeutics Market, by End User – Revenue and Forecast to 2030 (US$ Million)
Table 23. UK Microbiome Therapeutics Market, by Type – Revenue and Forecast to 2030 (US$ Million)
Table 24. UK Microbiome Therapeutics Market, by Therapeutics– Revenue and Forecast to 2030 (US$ Million)
Table 25. UK Microbiome Therapeutics Market, by Application– Revenue and Forecast to 2030 (US$ Million)
Table 26. UK Microbiome Therapeutics Market, by End User– Revenue and Forecast to 2030 (US$ Million)
Table 27. Germany Microbiome Therapeutics Market, by Type – Revenue and Forecast to 2030 (US$ Million)
Table 28. Germany Microbiome Therapeutics Market, by Therapeutics– Revenue and Forecast to 2030 (US$ Million)
Table 29. Germany Microbiome Therapeutics Market, by Application– Revenue and Forecast to 2030 (US$ Million)
Table 30. Germany Microbiome Therapeutics Market, by End User– Revenue and Forecast to 2030 (US$ Million)
Table 31. France Microbiome Therapeutics Market, by Type – Revenue and Forecast to 2030 (US$ Million)
Table 32. France Microbiome Therapeutics Market, by Therapeutics– Revenue and Forecast to 2030 (US$ Million)
Table 33. France Microbiome Therapeutics Market, by Application– Revenue and Forecast to 2030 (US$ Million)
Table 34. France Microbiome Therapeutics Market, by End User– Revenue and Forecast to 2030 (US$ Million)
Table 35. Italy Microbiome Therapeutics Market, by Type – Revenue and Forecast to 2030 (US$ Million)
Table 36. Italy Microbiome Therapeutics Market, by Therapeutics– Revenue and Forecast to 2030 (US$ Million)
Table 37. Italy Microbiome Therapeutics Market, by Application– Revenue and Forecast to 2030 (US$ Million)
Table 38. Italy Microbiome Therapeutics Market, by End User– Revenue and Forecast to 2030 (US$ Million)
Table 39. Spain Microbiome Therapeutics Market, by Type – Revenue and Forecast to 2030 (US$ Million)
Table 40. Spain Microbiome Therapeutics Market, by Therapeutics– Revenue and Forecast to 2030 (US$ Million)
Table 41. Spain Microbiome Therapeutics Market, by Application– Revenue and Forecast to 2030 (US$ Million)
Table 42. Spain Microbiome Therapeutics Market, by End User– Revenue and Forecast to 2030 (US$ Million)
Table 43. Rest of Europe Microbiome Therapeutics Market, by Type – Revenue and Forecast to 2030 (US$ Million)
Table 48. Rest of Europe Microbiome Therapeutics Market, by Therapeutics– Revenue and Forecast to 2030 (US$ Million)
Table 49. Rest of Europe Microbiome Therapeutics Market, by Application– Revenue and Forecast to 2030 (US$ Million)
Table 50. Rest of Europe Microbiome Therapeutics Market, by End User– Revenue and Forecast to 2030 (US$ Million)
Table 51. Asia Pacific Microbiome Therapeutics Market, by Type – Revenue and Forecast to 2030 (US$ Million)
Table 52. Asia Pacific Microbiome Therapeutics Market, by Therapeutics – Revenue and Forecast to 2030 (US$ Million)
Table 53. Asia Pacific Microbiome Therapeutics Market, by Application – Revenue and Forecast to 2030 (US$ Million)
Table 54. Asia Pacific Microbiome Therapeutics Market, by End User – Revenue and Forecast to 2030 (US$ Million)
Table 55. China Microbiome Therapeutics Market, by Type – Revenue and Forecast to 2030 (US$ Million)
Table 56. China Microbiome Therapeutics Market, by Therapeutics – Revenue and Forecast to 2030 (US$ Million)
Table 57. China Microbiome Therapeutics Market, by Application – Revenue and Forecast to 2030 (US$ Million)
Table 58. China Microbiome Therapeutics Market, by End User – Revenue and Forecast to 2030 (US$ Million)
Table 59. Japan Microbiome Therapeutics Market, by Type – Revenue and Forecast to 2030 (US$ Million)
Table 60. Japan Microbiome Therapeutics Market, by Therapeutics – Revenue and Forecast to 2030 (US$ Million)
Table 61. Japan Microbiome Therapeutics Market, by Application – Revenue and Forecast to 2030 (US$ Million)
Table 62. Japan Microbiome Therapeutics Market, by End User – Revenue and Forecast to 2030 (US$ Million)
Table 63. India Microbiome Therapeutics Market, by Type – Revenue and Forecast to 2030 (US$ Million)
Table 64. India Microbiome Therapeutics Market, by Therapeutics – Revenue and Forecast to 2030 (US$ Million)
Table 65. India Microbiome Therapeutics Market, by Application – Revenue and Forecast to 2030 (US$ Million)
Table 66. India Microbiome Therapeutics Market, by End User – Revenue and Forecast to 2030 (US$ Million)
Table 67. Australia Microbiome Therapeutics Market, by Type – Revenue and Forecast to 2030 (US$ Million)
Table 68. Australia Microbiome Therapeutics Market, by Therapeutics – Revenue and Forecast to 2030 (US$ Million)
Table 69. Australia Microbiome Therapeutics Market, by Application – Revenue and Forecast to 2030 (US$ Million)
Table 70. Australia Microbiome Therapeutics Market, by End User – Revenue and Forecast to 2030 (US$ Million)
Table 71. South Korea Microbiome Therapeutics Market, by Type – Revenue and Forecast to 2030 (US$ Million)
Table 72. South Korea Microbiome Therapeutics Market, by Therapeutics – Revenue and Forecast to 2030 (US$ Million)
Table 73. South Korea Microbiome Therapeutics Market, by Application – Revenue and Forecast to 2030 (US$ Million)
Table 74. South Korea Microbiome Therapeutics Market, by End User – Revenue and Forecast to 2030 (US$ Million)
Table 75. Rest of Asia Pacific Microbiome Therapeutics Market, by Type – Revenue and Forecast to 2030 (US$ Million)
Table 108. Rest of Asia Pacific Microbiome Therapeutics Market, by Therapeutics – Revenue and Forecast to 2030 (US$ Million)
Table 109. Rest of Asia Pacific Microbiome Therapeutics Market, by Application – Revenue and Forecast to 2030 (US$ Million)
Table 110. Rest of Asia Pacific Microbiome Therapeutics Market, by End User – Revenue and Forecast to 2030 (US$ Million)
Table 111. Middle East & Africa Microbiome Therapeutics Market, by Type – Revenue and Forecast to 2030 (US$ Million)
Table 112. Middle East & Africa Microbiome Therapeutics Market, by Therapeutics – Revenue and Forecast to 2030 (US$ Million)
Table 113. Middle East & Africa Microbiome Therapeutics Market, by Application – Revenue and Forecast to 2030 (US$ Million)
Table 114. Middle East & Africa Microbiome Therapeutics Market, by End User – Revenue and Forecast to 2030 (US$ Million)
Table 115. Saudi Arabia Microbiome Therapeutics Market, by Type – Revenue and Forecast to 2030 (US$ Million)
Table 116. Saudi Arabia Microbiome Therapeutics Market, by Therapeutics – Revenue and Forecast to 2030 (US$ Million)
Table 117. Saudi Arabia Microbiome Therapeutics Market, by Application – Revenue and Forecast to 2030 (US$ Million)
Table 118. Saudi Arabia Microbiome Therapeutics Market, by End User – Revenue and Forecast to 2030 (US$ Million)
Table 119. South Africa Microbiome Therapeutics Market, by Type – Revenue and Forecast to 2030 (US$ Million)
Table 120. South Africa Microbiome Therapeutics Market, by Therapeutics – Revenue and Forecast to 2030 (US$ Million)
Table 121. South Africa Microbiome Therapeutics Market, by Application – Revenue and Forecast to 2030 (US$ Million)
Table 122. South Africa Microbiome Therapeutics Market, by End User – Revenue and Forecast to 2030 (US$ Million)
Table 123. UAE Microbiome Therapeutics Market, by Type – Revenue and Forecast to 2030 (US$ Million)
Table 124. UAE Microbiome Therapeutics Market, by Therapeutics – Revenue and Forecast to 2030 (US$ Million)
Table 125. UAE Microbiome Therapeutics Market, by Application – Revenue and Forecast to 2030 (US$ Million)
Table 126. UAE Microbiome Therapeutics Market, by End User – Revenue and Forecast to 2030 (US$ Million)
Table 127. Rest of Middle East Africa Microbiome Therapeutics Market, by Type – Revenue and Forecast to 2030 (US$ Million)
Table 128. Rest of Middle East Africa Microbiome Therapeutics Market, by Therapeutics – Revenue and Forecast to 2030 (US$ Million)
Table 129. Rest of Middle East Africa Microbiome Therapeutics Market, by Application – Revenue and Forecast to 2030 (US$ Million)
Table 130. Rest of Middle East Africa Microbiome Therapeutics Market, by End User – Revenue and Forecast to 2030 (US$ Million)
Table 131. South & Central America Microbiome Therapeutics Market, by Type – Revenue and Forecast to 2030 (US$ Million)
Table 132. South & Central America Microbiome Therapeutics Market, by Therapeutics – Revenue and Forecast to 2030 (US$ Million)
Table 133. South & Central America Microbiome Therapeutics Market, by Application – Revenue and Forecast to 2030 (US$ Million)
Table 134. South & Central America Microbiome Therapeutics Market, by End User – Revenue and Forecast to 2030 (US$ Million)
Table 135. Brazil Microbiome Therapeutics Market, by Type – Revenue and Forecast to 2030 (US$ Million)
Table 136. Brazil Microbiome Therapeutics Market, by Therapeutics – Revenue and Forecast to 2030 (US$ Million)
Table 137. Brazil Microbiome Therapeutics Market, by Application – Revenue and Forecast to 2030 (US$ Million)
Table 138. Brazil Microbiome Therapeutics Market, by End User – Revenue and Forecast to 2030 (US$ Million)
Table 139. Argentina Microbiome Therapeutics Market, by Type – Revenue and Forecast to 2030 (US$ Million)
Table 140. Argentina Microbiome Therapeutics Market, by Therapeutics – Revenue and Forecast to 2030 (US$ Million)
Table 141. Argentina Microbiome Therapeutics Market, by Application – Revenue and Forecast to 2030 (US$ Million)
Table 142. Argentina Microbiome Therapeutics Market, by End User – Revenue and Forecast to 2030 (US$ Million)
Table 143. Rest of South & Central America Microbiome Therapeutics Market, by Type – Revenue and Forecast to 2030 (US$ Million)
Table 144. Rest of South & Central America Microbiome Therapeutics Market, by Therapeutics – Revenue and Forecast to 2030 (US$ Million)
Table 145. Rest of South & Central America Microbiome Therapeutics Market, by Application – Revenue and Forecast to 2030 (US$ Million)
Table 146. Rest of South & Central America Microbiome Therapeutics Market, by End User – Revenue and Forecast to 2030 (US$ Million)
Table 147. Recent Inorganic Growth Strategies in the Microbiome Therapeutics Market
Table 148. Recent Organic Growth Strategies in Microbiome Therapeutics Market
Table 149. Glossary of Terms, Microbiome Therapeutics Market
List of Figures
Figure 1. Microbiome Therapeutics Market Segmentation, By Geography
Figure 2. Global - PEST Analysis
Figure 3. Microbiome Therapeutics Market - Key Industry Dynamics
Figure 4. Impact Analysis of Drivers and Restraints
Figure 5. Microbiome Therapeutics Market Revenue (US$ Mn), 2020 – 2030
Figure 6. Microbiome Therapeutics Market Revenue, Geography (US$ Mn), 2022 – 2030
Figure 7. Microbiome Therapeutics Market Revenue Share, by Type, 2022 & 2030 (%)
Figure 8. Procedure: Microbiome Therapeutics Market – Revenue and Forecast to 2030 (US$ Million)
Figure 9. Therapeutics: Microbiome Therapeutics Market – Revenue and Forecast to 2030 (US$ Million)
Figure 10. Microbiome Therapeutics Market Revenue Share, by Application, 2022 & 2030 (%)
Figure 11. Metabolic Disorder and Obesity: Microbiome Therapeutics Market – Revenue and Forecast to 2030 (US$ Million)
Figure 12. C. Difficile Infection (CDI): Microbiome Therapeutics Market – Revenue and Forecast to 2030 (US$ Million)
Figure 13. Inflammatory Bowel Disease: Microbiome Therapeutics Market – Revenue and Forecast to 2030 (US$ Million)
Figure 14. Otehrs: Microbiome Therapeutics Market – Revenue and Forecast to 2030 (US$ Million)
Figure 15. Microbiome Therapeutics Market Revenue Share, End User, 2022 & 2030 (%)
Figure 16. Hospitals and Clinics: Microbiome Therapeutics Market – Revenue and Forecast to 2030 (US$ Million)
Figure 17. Ambulatory Surgical Centers: Microbiome Therapeutics Market – Revenue and Forecast to 2030 (US$ Million)
Figure 18. Homecare: Microbiome Therapeutics Market – Revenue and Forecast to 2030 (US$ Million)
Figure 19. Others: Microbiome Therapeutics Market – Revenue and Forecast to 2030 (US$ Million)
Figure 20. North America: Microbiome Therapeutics Market, by Key Country – Revenue (2022) (US$ Million)
Figure 21. North America Microbiome Therapeutics Market Revenue and Forecast to 2030 (US$ Mn)
Figure 22. North America Microbiome Therapeutics Market, By Key Countries, 2022 and 2030 (%)
Figure 23. US Microbiome Therapeutics Market Revenue and Forecast to 2030 (US$ Mn)
Figure 24. Canada Microbiome Therapeutics Market Revenue and Forecast to 2030 (US$ Mn)
Figure 25. Mexico Microbiome Therapeutics Market Revenue and Forecast to 2030 (US$ Mn)
Figure 26. Europe Microbiome Therapeutics Market, by Key Country – Revenue, 2022 (US$ Million)
Figure 27. Europe Microbiome Therapeutics Market Revenue and Forecast to 2030 (US$ Mn)
Figure 28. Europe Microbiome Therapeutics Market, By Key Countries, 2022 and 2030 (%)
Figure 29. UK Microbiome Therapeutics Market Revenue and Forecast to 2030 (US$ Mn)
Figure 30. Germany Microbiome Therapeutics Market Revenue and Forecast to 2030 (US$ Mn)
Figure 31. France Microbiome Therapeutics Market Revenue and Forecast to 2030 (US$ Mn)
Figure 32. Italy Microbiome Therapeutics Market Revenue and Forecast to 2030 (US$ Mn)
Figure 33. Spain Microbiome Therapeutics Market Revenue and Forecast to 2030 (US$ Mn)
Figure 34. Rest of Europe Microbiome Therapeutics Market Revenue and Forecast to 2030 (US$ Mn)
Figure 36. Asia Pacific Microbiome Therapeutics Market, by Key Country – Revenue, 2022 (US$ Million)
Figure 37. Asia Pacific Microbiome Therapeutics Market Revenue and Forecast to 2030 (US$ Mn)
Figure 38. Asia Pacific Microbiome Therapeutics Market, By Key Countries, 2022 and 2030 (%)
Figure 39. China Microbiome Therapeutics Market Revenue and Forecast to 2030 (US$ Mn)
Figure 40. Japan Microbiome Therapeutics Market Revenue and Forecast to 2030 (US$ Mn)
Figure 41. India Microbiome Therapeutics Market Revenue and Forecast to 2030 (US$ Mn)
Figure 42. Australia Microbiome Therapeutics Market Revenue and Forecast to 2030 (US$ Mn)
Figure 43. South Korea Microbiome Therapeutics Market Revenue and Forecast to 2030 (US$ Mn)
Figure 44. Rest of Asia Pacific Microbiome Therapeutics Market Revenue and Forecast to 2030 (US$ Mn)
Figure 53. Middle East & Africa Microbiome Therapeutics Market, by Key Country – Revenue, 2022 (US$ Million)
Figure 54. Middle East & Africa Microbiome Therapeutics Market Revenue and Forecast to 2030 (US$ Mn)
Figure 55. Middle East & Africa Microbiome Therapeutics Market, By Key Countries, 2022 and 2030 (%)
Figure 56. Saudi Arabia Microbiome Therapeutics Market Revenue and Forecast to 2030 (US$ Mn)
Figure 57. South Africa Microbiome Therapeutics Market Revenue and Forecast to 2030 (US$ Mn)
Figure 58. UAE Microbiome Therapeutics Market Revenue and Forecast to 2030 (US$ Mn)
Figure 59. Rest of Middle East Africa Microbiome Therapeutics Market Revenue and Forecast to 2030 (US$ Mn)
Figure 60. South & Central America Microbiome Therapeutics Market, by Key Country – Revenue, 2022 (US$ Million)
Figure 61. South & Central America Microbiome Therapeutics Market Revenue and Forecast to 2030 (US$ Mn)
Figure 62. South & Central America Microbiome Therapeutics Market, By Key Countries, 2022 and 2030 (%)
Figure 63. Brazil Microbiome Therapeutics Market Revenue and Forecast to 2030 (US$ Mn)
Figure 64. Argentina Microbiome Therapeutics Market Revenue and Forecast to 2030 (US$ Mn)
Figure 65. Rest of South & Central America Microbiome Therapeutics Market Revenue and Forecast to 2030 (US$ Mn)
Figure 66. Growth Strategies in Microbiome Therapeutics Market
The List of Companies - Microbiome Therapeutics Market
- Enterome
- Finch Therapeutics Group Inc
- Caelus Health
- Ferring Pharmaceuticals
- Pendulum Therapeutics Inc.
- AOBiome
- Seres Therapeutics
- Vedanta Biosciences
- COST-BRY Pty Ltd (BiomeBank)
- YSOPIA Bioscienceare
The Insight Partners performs research in 4 major stages: Data Collection & Secondary Research, Primary Research, Data Analysis and Data Triangulation & Final Review.
- Data Collection and Secondary Research:
As a market research and consulting firm operating from a decade, we have published many reports and advised several clients across the globe. First step for any study will start with an assessment of currently available data and insights from existing reports. Further, historical and current market information is collected from Investor Presentations, Annual Reports, SEC Filings, etc., and other information related to company’s performance and market positioning are gathered from Paid Databases (Factiva, Hoovers, and Reuters) and various other publications available in public domain.
Several associations trade associates, technical forums, institutes, societies and organizations are accessed to gain technical as well as market related insights through their publications such as research papers, blogs and press releases related to the studies are referred to get cues about the market. Further, white papers, journals, magazines, and other news articles published in the last 3 years are scrutinized and analyzed to understand the current market trends.
- Primary Research:
The primarily interview analysis comprise of data obtained from industry participants interview and answers to survey questions gathered by in-house primary team.
For primary research, interviews are conducted with industry experts/CEOs/Marketing Managers/Sales Managers/VPs/Subject Matter Experts from both demand and supply side to get a 360-degree view of the market. The primary team conducts several interviews based on the complexity of the markets to understand the various market trends and dynamics which makes research more credible and precise.
A typical research interview fulfils the following functions:
- Provides first-hand information on the market size, market trends, growth trends, competitive landscape, and outlook
- Validates and strengthens in-house secondary research findings
- Develops the analysis team’s expertise and market understanding
Primary research involves email interactions and telephone interviews for each market, category, segment, and sub-segment across geographies. The participants who typically take part in such a process include, but are not limited to:
- Industry participants: VPs, business development managers, market intelligence managers and national sales managers
- Outside experts: Valuation experts, research analysts and key opinion leaders specializing in the electronics and semiconductor industry.
Below is the breakup of our primary respondents by company, designation, and region:
Once we receive the confirmation from primary research sources or primary respondents, we finalize the base year market estimation and forecast the data as per the macroeconomic and microeconomic factors assessed during data collection.
- Data Analysis:
Once data is validated through both secondary as well as primary respondents, we finalize the market estimations by hypothesis formulation and factor analysis at regional and country level.
- 3.1 Macro-Economic Factor Analysis:
We analyse macroeconomic indicators such the gross domestic product (GDP), increase in the demand for goods and services across industries, technological advancement, regional economic growth, governmental policies, the influence of COVID-19, PEST analysis, and other aspects. This analysis aids in setting benchmarks for various nations/regions and approximating market splits. Additionally, the general trend of the aforementioned components aid in determining the market's development possibilities.
- 3.2 Country Level Data:
Various factors that are especially aligned to the country are taken into account to determine the market size for a certain area and country, including the presence of vendors, such as headquarters and offices, the country's GDP, demand patterns, and industry growth. To comprehend the market dynamics for the nation, a number of growth variables, inhibitors, application areas, and current market trends are researched. The aforementioned elements aid in determining the country's overall market's growth potential.
- 3.3 Company Profile:
The “Table of Contents” is formulated by listing and analyzing more than 25 - 30 companies operating in the market ecosystem across geographies. However, we profile only 10 companies as a standard practice in our syndicate reports. These 10 companies comprise leading, emerging, and regional players. Nonetheless, our analysis is not restricted to the 10 listed companies, we also analyze other companies present in the market to develop a holistic view and understand the prevailing trends. The “Company Profiles” section in the report covers key facts, business description, products & services, financial information, SWOT analysis, and key developments. The financial information presented is extracted from the annual reports and official documents of the publicly listed companies. Upon collecting the information for the sections of respective companies, we verify them via various primary sources and then compile the data in respective company profiles. The company level information helps us in deriving the base number as well as in forecasting the market size.
- 3.4 Developing Base Number:
Aggregation of sales statistics (2020-2022) and macro-economic factor, and other secondary and primary research insights are utilized to arrive at base number and related market shares for 2022. The data gaps are identified in this step and relevant market data is analyzed, collected from paid primary interviews or databases. On finalizing the base year market size, forecasts are developed on the basis of macro-economic, industry and market growth factors and company level analysis.
- Data Triangulation and Final Review:
The market findings and base year market size calculations are validated from supply as well as demand side. Demand side validations are based on macro-economic factor analysis and benchmarks for respective regions and countries. In case of supply side validations, revenues of major companies are estimated (in case not available) based on industry benchmark, approximate number of employees, product portfolio, and primary interviews revenues are gathered. Further revenue from target product/service segment is assessed to avoid overshooting of market statistics. In case of heavy deviations between supply and demand side values, all thes steps are repeated to achieve synchronization.
We follow an iterative model, wherein we share our research findings with Subject Matter Experts (SME’s) and Key Opinion Leaders (KOLs) until consensus view of the market is not formulated – this model negates any drastic deviation in the opinions of experts. Only validated and universally acceptable research findings are quoted in our reports.
We have important check points that we use to validate our research findings – which we call – data triangulation, where we validate the information, we generate from secondary sources with primary interviews and then we re-validate with our internal data bases and Subject matter experts. This comprehensive model enables us to deliver high quality, reliable data in shortest possible time.
Get Free Sample For